pISSN 1226-6051
eISSN 2508-786X

Table. 4.

Table. 4.

Prognostic factors of progression-free survival (PFS)

Variables Univariate analysis (Log rank test) Multivariable analysis (Cox proportional hazard model)


Number of patients (Progressed/Total) Median PFS (months) p HR 95% CI p
Age, years
<65
≥65
76/93
55/63
8.27
8.40
0.250
Sex
Male
Female
103/121
28/35
8.40
8.27
0.563
KPSa
<80%
≥80%
12/12
87/108
10.00
2.90
<0.001 3.46 1.18–10.12 0.023
Nephrectomy
Yes
No
112/135
19/21
9.10
6.17
0.066
Histology
Non-clear cell
Clear cell
7/8
124/148
5.70
8.40
0.185
Prior therapy
Yes
No
34/41
97/115
8.87
8.23
0.298
Time from diagnosis to systemic treatment
<1 year
≥1 years
84/94
46/61
7.47
11.33
0.004 2.48 1.10–5.60 0.028
Number of metastases
1
≥2
47/60
84/96
11.33
7.70
0.013
Anemia
Yes
No
77/87
54/69
10.97
7.83
0.049
Thrombosis
Yes
No
14/16
117/140
6.07
9.00
0.118
Neutrophilia
Yes
No
8/10
123/146
4.33
8.40
0.775
Hypercalcemia
Yes
No
16/18
115/138
3.73
9.43
0.003
Elevated LDH
Yes
No
3/4
64/75
1.97
8.03
0.810
Pre-treatment NLR
≥3
>3
92/113
39/43
9.80
5.30
0.001
Sunitinib-induced hypothyroidism
Overt
Subclinical
Euthyroid
40/51
28/35
63/70
12.20
6.17
6.07
0.001 0.38 0.16–0.88 0.024
Sunitinib-induced hypertension
Yes
No
35/48
96/108
12.60
7.00
<0.001
Sunitinib-induced proteinuria
Yes
No
50/63
81/93
10.47
7.83
0.042
Sunitinib-induced renal insufficiency
Yes
No
19/23
112/133
10.50
8.23
0.107

CI: confidence interval, HR: hazard ratio, KPS: Karnofsky performance score, LDH: lactate dehydrogenase, NLR: neutrophil lymphocyte ratio,

PFS: progression-free survival

a)Evaluated in 120 patients, b)Evaluated in 79 patients

Korean J Clin Pharm 2024;34:184-93 https://doi.org/10.24304/kjcp.2024.34.3.184
© 2024 Korean J Clin Pharm